Compare Campbell Soup Co. (CPB) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs ResMed Inc. — how do they compare? Campbell Soup Co. trades at $19.31 (market cap $5.78B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 5.5× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and ResMed Inc. for 51 Days on average.
| CPB | RMD | |
|---|---|---|
Market Cap | $5.78B | $31.89B |
Volume | 11,705,427 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $277.88 |
52-Week Low | $18.90 | $182.82 |
Typical Hold Time | 98 Days | 51 Days |
Enterprise Value | $12.83B | $31.24B |
Dividend Yield | 5.16% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical indicators. The company faces margin compression with net income margin at 4.14% and recently cut its dividend by 36% to strengthen the balance sheet. Revenue grew to $10.25B in 2025 but profitability remains under pressure. Analyst consensus shows cautious sentiment with 55% hold ratings and a $19.67 price target.
The outlook remains challenging with weak FY2027 guidance and ongoing restructuring. The $500 million cost savings program and Rao's brand growth offer potential upside, but investors face risks from declining sales, margin pressure, and competitive headwinds in the packaged foods sector.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
